Deutsche Bank (ETR:DBKGn) initiated coverage on shares of Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) with a Buy rating and a price target of $65.00. The firm's analysts cited the ...
Deutsche Bank initiated coverage of Biohaven (BHVN) with a Buy rating and $65 price target Maximize Your Portfolio with Data Driven ...
Spire Wealth Management bought a new position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) during the 4th quarter, ...
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...
Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of ...
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
Hosted on MSN14d
Pfizer settles Biohaven kickback claims case for $59.7mBiohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
Florida's Medicaid Fraud Control Unit secured the win through a multistate action. "Actions, like those alleged here, must be ...
Pfizer Settles Its Subsidiary’s Kickback Allegations for Nearly $60 Million - Pfizer Inc. agreed to pay over $59,746,277 to ...
Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...
A coalition consisting of the U.S. Department of Justice, 37 states, and Puerto Rico, filed suit against Biohaven ...
Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback